Novo Nordisk and Lilly Push GLP-1 Obesity Pills Toward Medicare Coverage
Novo Nordisk and Lilly unveiled competing GLP-1 obesity pills at ADA, with Medicare coverage set to expand to about $50 per month from July 1.
Markets, economy, and policy news for investors.
Investor topic hub
Macro stories that shape growth, inflation, labor markets, household spending, public budgets, and investor expectations.